Grufity logo
Grufity logo
SONN

SONN - Sonnet BioTherapeutics Holdings Inc Stock Price, Fair Value and News

$1.26 
Market Closed as of 02 Dec 2025, 04:00 pm ET

Price Targets

SONN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SONN Price Action

Last 7 days

-18.2%

Last 30 days

-21.7%

Last 90 days

14.5%

Trailing 12 Months

41.4%

SONN RSI Chart

SONN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SONN Valuation

Market Cap

8.9M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

8.92

EV/EBITDA

-0.66

Price/Free Cashflow

-0.7

SONN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

SONN Fundamentals

SONN Revenue

Revenue (TTM)

1.0M

SONN Earnings

Earnings (TTM)

-16.0M

Earnings Growth (Yr)

-78.48%

Earnings Growth (Qtr)

-47.89%

SONN Profitability

EBT Margin

-1579.31%

Return on Equity

-148.43%

Return on Assets

-107.57%

Free Cashflow Yield

-143.88%

SONN Investor Care

Shares Dilution (1Y)

988.35%

Diluted EPS (TTM)

-4.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025--1.0M-
2024--550.0K775.0K
2023198.5K173.3K100.0K325.0K
202211.4M5.9M349.9K257.4K
2021--22.5M16.9M
202028.0M---
201928.6M28.9M28.4M30.1M
201841.6M41.2M40.6M30.7M
201741.6M41.4M41.1M41.4M
201637.9M40.2M41.9M41.8M
201534.5M33.8M33.8M36.4M
201411.9M19.6M27.3M31.2M
20137.1M7.1M6.9M8.2M
20122.9M4.4M5.9M6.9M
2011549.3K539.2K1.0M1.5M
2010-447.4K291.9K136.3K
2009---603.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Sonnet BioTherapeutics Holdings Inc

SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEsonnetbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions

SONN is the stock ticker symbol of Sonnet BioTherapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Dec 02 2025, market cap of Sonnet BioTherapeutics Holdings Inc is 8.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Dec 02 2025, SONN's PE ratio (Price to Earnings) is -0.56 and Price to Sales (PS) ratio is 8.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SONN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Sonnet BioTherapeutics Holdings Inc has provided -0.703 (multiply by 100 for percentage) rate of return.